PERSPECTIVE; Systemic Therapy After Curative Local Treatment for Isolated Locoregional Recurrence in Triple-Negative Breast Cancer: Evidence Gaps and a Practical Clinical Framework

Veli Cakıcı (1)
(1) canakkale 18 mart üniversity, Turkey

Article Sidebar

Issue
Vol. 13 No. 2 (2026): In-Press Volume 13, Issue 2, May 2026
Keywords:
    Breast cancer, Triple-Negative, Diagnosis, Treatment, Local control, Adjuvant Chemotherapy, chemotherapy decision
No galleys available

Abstract

N/A

Full text article

Generated from XML file

References

Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. Apr 10 2018;36(11):1073-1079. doi:10.1200/JCO.2017.76.5719

Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci. Jan 31 2022;23(3). doi:10.3390/ijms23031665

Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. Jan 20 2020;38(3):203-213. doi:10.1200/JCO.19.00904

Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. Aug 10 2021;39(23):2539-2551. doi:10.1200/JCO.21.00976

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. Jun 24 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. Feb 27 2020;382(9):810-821. doi:10.1056/NEJMoa1901917

Ignatiadis M, Bailey A, McArthur H, et al. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. Jama. Jan 30 2025;333(13):1150-1160. doi:10.1001/jama.2024.26886

Nader-Marta G, Monteforte M, Agostinetto E, et al. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. Mar 2024;9(3):102390. doi:10.1016/j.esmoop.2024.102390

Zhang D, Jahanfar S, Rabinowitz JB, et al. Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Mar 12 2025;27(1):38. doi: 10.1186/s13058-025-01986-y

Xu J, Fang K, Li X, Han L, Sun S, Sun T. From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. Cancer Biol Med. Nov 28 2025;22(12):1493-1514. doi: 10.20892/j.issn.2095-3941.2025.0431

Authors

Veli Cakıcı
canakkale 18 mart üniversity
cakiciveli@gmail.com (Primary Contact)
1.
Cakıcı V. PERSPECTIVE; Systemic Therapy After Curative Local Treatment for Isolated Locoregional Recurrence in Triple-Negative Breast Cancer: Evidence Gaps and a Practical Clinical Framework. Arch Breast Cancer [Internet]. [cited 2026 Feb. 10];13(2). Available from: https://archbreastcancer.com/index.php/abc/article/view/1276
Download Citation
Endnote/Zotero/Mendeley (RIS)

Copyright (c) 2026 Archives of Breast Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.

Article Details